Positive Patient Stories™

Paratek Pharmaceuticals News

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle  
12/03/18Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030 
11/27/18Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections 
11/06/18Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results 
11/01/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
10/26/18Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018 
10/04/18Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline 
10/03/18Paratek Pharmaceuticals, Inc. to Host Investor Day on October 23, 2018 
10/02/18Paratek Announces FDA Approval of NUZYRA™ (Omadacycline) 
10/02/18FDA Approves SEYSARA™ (Sarecycline) for the Treatment of Moderate to Severe Acne 
10/01/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
09/25/18Paratek Pharmaceuticals Presenting New Omadacycline Data at IDWeek 2018 
09/04/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
08/29/18Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conference 
08/08/18FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline 
08/08/18Paratek Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Omadacycline New Drug Applications for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections 
08/02/18Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results 
07/23/18Paratek Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018 
06/20/18Paratek Announces FDA Advisory Committee Date for Omadacycline 
06/11/18Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus at ASM Microbe 2018 
06/07/18Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018 
06/01/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
05/22/18Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity 
05/09/18Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results 
05/01/18Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 
04/25/18Paratek Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018 
04/23/18Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID 
04/23/18Paratek Pharmaceuticals Presents New Microbiology Efficacy Data of Oral-only Omadacycline Against the Most Common Pathogens Associated with Skin Infections 
04/19/18Paratek Pharmaceuticals, Inc. Prices $140 Million of Convertible Senior Subordinated Notes due 2024 
04/18/18Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024 
04/13/18Paratek Appoints Rolf K. Hoffmann to Company’s Board of Directors 
04/12/18Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018 
04/04/18Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA 
03/30/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
03/28/18Paratek Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference 
03/16/18Paratek Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference 
03/02/18Paratek Pharmaceuticals to Present at the 38th Annual Cowen & Co. Health Care Conference 
03/01/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
03/01/18Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Remains on Track for Commercial Launch by First Quarter 2019 
02/15/18Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018 
02/05/18Paratek Completes Submission of New Drug Applications to U.S. Food and Drug Administration for Oral and Intravenous Omadacycline for Pneumonia and Skin Infections 
02/01/18Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
01/31/18Paratek Pharmaceuticals to Present at LEERINK Partners 7th Annual Global Healthcare Conference 
01/18/18Paratek Announces Pricing of Public Offering of Common Stock 
01/17/18Paratek Announces Public Offering of Common Stock 
01/03/18Paratek Provides Update on Pipeline Progress 

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.